YKYoshihisa Kitamura

Yoshihisa Kitamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshihisa Kitamura has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Takashi Taniguchi

    Department of Neurobiology, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto, Japan

    23 shared publications
  • Kazuyuki Takata

    Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan

    17 shared publications
  • Masatoshi Inden

    Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto, Japan

    13 shared publications
  • Shun Shimohama

    Department of Neurology, School of Medicine, Sapporo Medical University, Sapporo, Japan

    11 shared publications
  • Kanji Yoshimoto

    Department of Food Sciences and Biotechnology, Faculty of Life Science, Hiroshima Institute of Technology, 2-1-1 Miyake, Saeki-ku, Hiroshima 731-5193, Japan

    6 shared publications
  • Akinori Akaike

    Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University

    5 shared publications

Latest Publications

  • Pharmacological assessment of methamphetamine-induced behavioral hyperactivity mediated by dopaminergic transmission in planarian Dugesia japonica

    by Natsuka Tashiro, Kaneyasu Nishimura, Kanako Daido, Tomoe Oka, Mio Todo, Asami Toshikawa, Jun Tsushima, Kazuyuki Takata, Eishi Ashihara, Kanji Yoshimoto, et al.


  • Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone‐treated parkinsonian mice

    by Masatoshi Inden, Kazuyuki Takata, Kaneyasu Nishimura, Yoshihisa Kitamura, Eishi Ashihara, Kanji Yoshimoto, Hiroyoshi Ariga, Osamu Honmou, Shun Shimohama

    To appreciate the potential applications of stem cell technology in neurodegenerative diseases, including Parkinson's disease (PD), it is important to understand the characteristics of the various types of stem cells. In this study, we designed a set of experiments to compare the ability of three types of human stem cells—mesenchymal stem cells (MSCs), bone marrow CD34+cells (BM), and cord blood CD34+cells (CB)—using rotenone‐treated NOD/SCID mice. Rotenone was orally administered once daily at a dose of 30 mg/kg for 56 days to induce a parkinsonian phenotype. Intravenous delivery of CB into rotenone‐treated mice was slightly more beneficial than that of MSCs or BM according to both histological and behavioral analyses. Human nucleus (hNu)+cells, which are a specific marker of human cells, were observed in the striatum of rotenone‐treated mice transplanted with stem cells. These hNu+cells expressed tyrosine hydroxylase (TH). Additionally, α‐synuclein+/TH+cells in the substantia nigra pars compacta decreased significantly following stem cell transplantation. Immunohistochemical analysis also revealed that chronic exposure to rotenone decreased glial cell line‐derived neurotrophic factor immunoreactivity and that the reduction was improved by each stem cell transplantation. Gene expression analyses revealed that MSCs, BM, and CB expressed several neurotrophic factors. These results suggest that the beneficial effects of intravenous delivery of stem cells into rotenone‐treated mice may result not only from a neurotrophic effect but also from endogenous brain repair mechanisms and the potential of intravenous delivery of stem cells derived from an autologous source for clinical applications in PD.


  • Open Access

    Effect of Selective Serotonin Reuptake Inhibitors via 5-HT1A Receptors on L-DOPA-Induced Rotational Behavior in a Hemiparkinsonian Rat Model

    by Masatoshi Inden, Mari Abe, Hideaki Minamino, Kazuyuki Takata, Kanji Yoshimoto, Ikuo Tooyama, Yoshihisa Kitamura

    L-Dihydroxyphenylalanine (L-DOPA) is considered the gold standard for the treatment of Parkinson’s disease (PD). However, long-term administration of L-DOPA can induce abnormal side effects. On the other hand, selective serotonin reuptake inhibitors (SSRIs) including fluoxetine have gained tremendous popularity in the treatment of depression in PD. SSRIs are thought to influence motor function in PD via pharmacological modification of interactions between serotonergic and dopaminergic networks, which are complex and not yet fully understand. In this study, intranigral injection of 6-hydroxydopamine (6-OHDA) in rats caused a significant loss of tyrosine hydroxylase immunoreactivity in the striatum and substantia nigra. However, tryptophan hydroxylase immunoreactivity of the striatum and raphe nucleus was unaffected by 6-OHDA. Immunohistochemical analysis reveal that the serotonergic system was unaffected by the injection of 6-OHDA. We demonstrated also that pre-treatment with fluoxetine significantly suppressed L-DOPA-induced rotational behavior. Additionally, fluoxetine suppressed L-DOPA-induced ERK1/2 and histone H3 phosphorylation. These effects of fluoxetine were abolished by pre-treatment with WAY 100135, a 5-HT1A antagonist. These results suggest that fluoxetine may influence motor function in PD via pharmacological modification of interactions between serotonergic and dopaminergic neuronal networks.


  • Open Access

    Regeneration of dopaminergic neurons after 6‐hydroxydopamine‐induced lesion in planarian brain

    by Kaneyasu Nishimura, Takeshi Inoue, Kanji Yoshimoto, Takashi Taniguchi, Yoshihisa Kitamura, Kiyokazu Agata

    J. Neurochem. (2011) 10.1111/j.1471‐4159.2011.07518.x Planarians have robust regenerative ability dependent on X‐ray‐sensitive pluripotent stem cells, called neoblasts. Here, we report that planarians can regenerate dopaminergic neurons after selective degeneration of these neurons caused by treatment with a dopaminergic neurotoxin (6‐hydroxydopamine; 6‐OHDA). This suggests that planarians have a system to sense the degeneration of dopaminergic neurons and to recruit stem cells to produce dopaminergic neurons to recover brain morphology and function. We confirmed that X‐ray‐irradiated planarians do not regenerate brain dopaminergic neurons after 6‐OHDA‐induced lesioning, suggesting that newly generated dopaminergic neurons are indeed derived from pluripotent stem cells. However, we found that the majority of regenerated dopaminergic neurons were 5‐bromo‐2′‐deoxyuridine‐negative cells. Therefore, we carefully analyzed when proliferating stem cells became committed to become dopaminergic neurons during regeneration by a combination of 5‐bromo‐2′‐deoxyuridine pulse‐chase experiments, immunostaining/in situ hybridization, and 5‐fluorouracil treatment. The results strongly suggested that G2‐phase stem cells become committed to dopaminergic neurons in the mesenchymal space around the brain, after migration from the trunk region following S‐phase. These new findings obtained from planarian regeneration provide hints about how to conduct cell‐transplantation therapy for future regenerative medicine.


  • Open Access

    Neuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson's disease and stroke model rats

    by Yoshihisa Kitamura, Shotaro Watanabe, Masanobu Taguchi, Kentaro Takagi, Takuya Kawata, Kazuko Takahashi-Niki, Hiroyuki Yasui, Hiroshi Maita, Sanae Mm Iguchi-Ariga, Hiroyoshi Ariga

    Background: Parkinson's disease (PD) and cerebral ischemia are chronic and acute neurodegenerative diseases, respectively, and onsets of these diseases are thought to be induced at least by oxidative stress. PD is caused by decreased dopamine levels in the substantia nigra and striatum, and cerebral ischemia occurs as a result of local reduction or arrest of blood supply. Although a precursor of dopamine and inhibitors of dopamine degradation have been used for PD therapy and an anti-oxidant have been used for cerebral ischemia therapy, cell death progresses during treatment. Reagents that prevent oxidative stress-induced cell death are therefore necessary for fundamental therapies for PD and cerebral ischemia. DJ-1, a causative gene product of a familial form of PD, PARK7, plays roles in transcriptional regulation and anti-oxidative stress, and loss of its function is thought to result in the onset of PD. Superfluous oxidation of cysteine at amino acid 106 (C106) of DJ-1 renders DJ-1 inactive, and such oxidized DJ-1 has been observed in patients with the sporadic form of PD. Results: In this study, a compound, comp-23, that binds to DJ-1 was isolated by virtual screening. Comp-23 prevented oxidative stress-induced death of SH-SY5Y cells and primary neuronal cells of the ventral mesencephalon but not that of DJ-1-knockdown SH-SY5Y cells, indicating that the effect of the compound is specific to DJ-1. Comp-23 inhibited the production of reactive oxygen species (ROS) induced by oxidative stress and prevented excess oxidation of DJ-1. Furthermore, comp-23 prevented dopaminergic cell death in the substantia nigra and restored movement abnormality in 6-hydroxyldopamine-injected and rotenone-treated PD model rats and mice. Comp-23 also reduced infarct size of cerebral ischemia in rats that had been induced by middle cerebral artery occlusion. Protective activity of comp-23 seemed to be stronger than that of previously identified compound B. Conclusions: The results indicate that comp-23 exerts a neuroprotective effect by reducing ROS-mediated neuronal injury, suggesting that comp-23 becomes a lead compound for PD and ischemic neurodegeneration therapies.


  • Detoxification of 6-hydroxydopamine-induced Parkinsonian neurodegeneration by G-CYPMPO, a novel radical trapper

    by Yoshihisa Kitamura, Masato Kamibayashi, Masatoshi Inden, Takashi Yanagida, Tomonori Shibaike, Kazuyuki Takata, Hiroyuki Yasui, Masayuki Yamashita, Takashi Taniguchi


  • Open Access

    Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors

    by Kazuyuki Takata, Yoshihisa Kitamura, Mana Saeki, Maki Terada, Sachiko Kagitani, Risa Kitamura, Yasuhiro Fujikawa, Alfred Maelicke, Hidekazu Tomimoto, Takashi Taniguchi, et al.


  • [Dopaminergic neuroprotection and reconstruction of neural network tiara].

    by Yoshihisa Kitamura

    Parkinson's disease (PD) is an age-related neurodegenerative disorder in whose brain massive loss of dopaminergic neurons and formation of Lewy bodies occur in the substantia nigra (SN). L-Dihydroxyphenylamine (L-DOPA) substitution is still considered the gold standard of antiparkinsonian drug therapy. However, there has been little information available on neuroprotective and regenerative therapies. Recently, we have found that pramipexole and talipexole (D2/D3-dopaminergic agonists) inhibit dopaminergic neurotoxin-induced production of reactive oxygen species and apoptotic cell death. In addition, treatment with these drugs induces enhancement of anti-apoptotic Bcl-2 expression and inhibition of α-synuclein aggregation. Interestingly, recent study suggests that pramipexole treatment delays the progression of early PD symptom. On the other hand, we investigated the transplantation strategy for PD by assessing whether double-transplants of mouse embryonic stem (ES) cell-derived neurons in the striatum (ST) and SN, or subthalamic nucleus (STN), induce functional recovery in rat hemi-parkinsonian model. The study indicates that both the involvement of ST as a place of transplantation and the number of ES cell-derived neurons are essential factors for efficacy on PD animal model. Interestingly, an invertebrate planarian can regenerate complete organs, including a well-organized central nervous system (brain), within about 7 days. The regeneration process of the planarian dopaminergic neural network (tiara) may be divided into five steps: 1) anterior blastema formation, 2) brain rudiment formation, 3) brain pattern formation, 4) the formation of dopaminergic tiara, and 5) functional recovery of dopaminergic motor regulation, with several kinds of genes and molecular cascades acting at each step.


  • The 6‐hydroxydopamine‐induced nigrostriatal neurodegeneration produces microglia‐like NG2 glial cells in the rat substantia nigra

    by Yoshihisa Kitamura, Masatoshi Inden, Hideaki Minamino, Mari Abe, Kazuyuki Takata, Takashi Taniguchi

    Neuron/glial 2 (NG2)‐expressing cells are often referred to as oligodendrocyte precursor cells. NG2‐expressing cells have also been identified as multipotent progenitor cells. However, microglia‐like NG2 glial cells have not been fully examined in neurodegenerative disorders such as Parkinson's disease (PD). In the present study, we chose two rat models of PD, i.e., intranigral or intrastriatal injection of 6‐hydroxydopamine (6‐OHDA), since the cell bodies of dopamine (DA) neurons, which form a nigrostriatal pathway, are in the substantia nigra pars compacta (SNpc) while their nerve terminals are in the striatum. In the nigral 6‐OHDA‐injected model, activated NG2‐positive cells were detected in the SNpc but not in the striatum. In contrast, in the striatal 6‐OHDA‐injected model, these cells were detected in both the SNpc and the striatum. In both models, activated NG2‐positive cells were located close to surviving tyrosine hydroxylase (TH)‐positive neurons in the SNpc. In addition, activated NG2‐positive cells in the SNpc coexpressed ionized calcium‐binding adaptor molecule 1 (Iba1), a microglia/macrophage marker. Interestingly, these double‐positive glial cells coexpressed glial cell line‐derived neurotrophic factor (GDNF). These results suggest that microglia‐like NG2 glial cells may help protect DA neurons and may lead to new therapeutic targets in PD.


  • Open Access

    Oxidative Neurodegeneration Is Prevented by UCP0045037, an Allosteric Modulator for the Reduced Form of DJ-1, a Wild-Type of Familial Parkinson’s Disease-Linked PARK7

    by Koichiro Yamane, Yoshihisa Kitamura, Takashi Yanagida, Kazuyuki Takata, Daijiro Yanagisawa, Takashi Taniguchi, Takahiro Taira, Hiroyoshi Ariga

    Although a loss-of-function mutation has been identified in familial Parkinson’s disease PARK7, the wild-type of DJ-1 is known to act as an oxidative stress sensor in neuronal cells. Recently, we identified UCP0045037 as a compound that bound to the reduced form of DJ-1 by in silico virtual screening. In this study, we determined the neuroprotective effects of UCP0045037 against focal cerebral ischemia-induced neurodegeneration in rats. Hydrogen peroxide-induced cell death was significantly inhibited by UCP0045037 in both rat mesencephalic dopaminergic neurons and human normal SH-SY5Y cells. In contrast, DJ-1-knockdown SH-SY5Y cells lost the protective activity of UCP0045037. These results suggest that UCP0045037 interacts with endogenous DJ-1 and produces a neuroprotective response.